Statin use* | |||||
---|---|---|---|---|---|
Overall | Events | No (reference) | Yes | p Value | |
n | n (%) | HR | HR (95% CI) | ||
Haemorrhagic stroke | |||||
Crude | 67 882 | 421 (0.62) | 1.00 | 1.21 (0.96 to 1.53) | 0.108 |
Age adjusted | 67 882 | 421 (0.62) | 1.00 | 1.07 (0.85 to 1.35) | 0.562 |
Model 1† | 60 353 | 371 (0.61) | 1.00 | 0.98 (0.76 to 1.27) | 0.895 |
Model 2‡ | 58 135 | 360 (0.62) | 1.00 | 0.94 (0.70 to 1.28) | 0.709 |
Effect modification§ | |||||
Antiplatelet agents¶ | 0.011 | ||||
No | 48 879 | 287 (0.59) | 1.00 | 0.80 (0.58 to 1.09) | |
Yes | 11 474 | 84 (0.73) | 1.00 | 1.59 (1.03 to 2.47) | |
Anticoagulants¶ | 0.719 | ||||
No | 60 009 | 361 (0.60) | 1.00 | 0.98 (0.75 to 1.26) | |
Yes | 344 | 10 (2.91) | 1.00 | 1.24 (0.35 to 4.38) |
*Statin use is modelled as time varying covariate. That is, USE(t)=0 when patient is not taking statin and USE(t)=1 once patient begins taking statin.
†Model 1 adjusted for age, income, marital status, enrolment status in the HT, DM and extension study, baseline history of cerebrovascular disease, hypertension, use of antiplatelet agents and anticoagulants.
‡Model 2 adjusted for variables in model 1 plus BMI, waist-to-hip ratio, physical activity, smoking status, baseline history of diabetes, baseline history of high cholesterol requiring pharmacological treatment and baseline history of cardiac disease.
§Adjusted for same variables as model 1 and include interactions terms, statin use and antiplatelet use, statin use and anticoagulant use.
¶Antiplatelet agents included aspirin, dipyridamole and ticlopidine; anticoagulants included warfarin and heparin. See text for definitions of each study variable.
BMI, body mass index; DM, dietary modification; HT, hormone therapy.